Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Innovation Council · Running

MPRD Innovative, minimally invasive Medical Prostatic Retraction Device for the treatment of Benign Prostatic Hyperplasia (BPH) Patients in the office settings.

Coordinator
Butterfly Medical Ltd, Israel
Runs
1 September 2023 to 31 August 2025
Status
Running
EU funding
€2.5m
Total cost
€4.8m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190156124

What the project is doing

In the project's own words, from its summary on CORDIS.

Butterfly Medical, a medical-device start-up, is developing a fast, simple, and minimally invasive alternative treatment to medication and surgery used for Benign Prostate Hyperplasia (BPH) treatment. Butterflys innovative device transfers the procedure from the operating room to the clinic, with the device being placed in 6 to 8 minutes, in doctors office, under local anaesthesia. Butterflys unique anatomically shaped proprietary nitinol implant is positioned in the prostatic urethra in order to open the urine path in the prostate for improved urine flow thereby relieving BPH symptoms.

Implant doesnt require any resection, cutting, or ablation of prostatic tissue. FIH clinical trials involving 85 patients performed in leading medical centres in Israel show a high degree of safety and effectiveness. Through this EIC project, Butterfly will undertake post-marketing studies in leading medical centres in Europe, and pivotal FDA study in the US.

Topics

Who is involved

OrganisationCityCountryRole
Butterfly Medical LtdYokneamIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI